(Q36824553)

English

Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia

scientific article published on 17 May 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

author name string

Finke J

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Nagler A

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

publication date

17 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1357-1362

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

21 January 2018

Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic marrow transplantation for acute non-lymphoblastic leukemia in relapse using fractionated total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404741

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404741

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36824553&oldid=2219365716"